Sergio Vázquez Estévez

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer, Paul Russo, Viktor Grünwald et al. · The Lancet · 2023 · 172 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

Ricardo Hitt, Alicia Lozano, Lara Iglesias Docampo et al. · Oral Oncology · 2022 · 16 citations

Medicine, Oncology, Radiation Oncology +13

Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

Giuseppe Procopio, Aristotelis Bamias, Manuela Schmidinger et al. · Clinical Genitourinary Cancer · 2019 · 12 citations · Full text

Medicine, Oncology, Pharmacology +9

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

Carlos Aguado, Patricia Cruz Castellanos, Martín Lázaro-Quintela et al. · Lung Cancer · 2022 · 11 citations · Full text

Medicine, Oncology, Pharmacology +14